UBS has upgraded its recommendation on Ipsen from 'neutral' to 'buy', with a target price raised sharply from €113 to €150, a new target that holds a potential 26% upside for the French pharmaceutical company's stock.

Seeing in Ipsen a 'superior growth profile but trading at a discount', the broker sees 'more room for revaluation as Ipsen continually demonstrates its ability to replenish its pipeline'.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.